← Eichor
Study identifier: NCT04415892 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Role of TRP Channels in CIPN

Condition: Chemotherapy-induced Peripheral Neuropathy  ·  Sponsor: Universitaire Ziekenhuizen KU Leuven

PhaseNA
Planned participants240
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersYes

About this study

Part I: Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in healthy, male volunteers. In addition, the inter-period and inter-hand reproducibility of the increase in dermal blood flow will be assessed. Part II: Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in patients suffering from chemotherapy-induced peripheral neuropathy compared to matched healthy volunteers. Part III: Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in patients who are treated with paclitaxel or oxaliplatin.

This description comes directly from the study's public registry record.

Talk to the study team

Heleen Marynissen, MD  ·  +3216347014  ·  heleen.marynissen@uzleuven.be

Always discuss trial participation with your own doctor first.

Locations (1)

KU LeuvenLeuven, Vlaams-Brabant, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04415892